Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts.

Nicolas Diehm, Florian Dick, Thomas Schaffner, Juerg Schmidli, Christoph Kalka, Stefano Di Santo, Jan Voelzmann, Iris Baumgartner

Journal: Progress in cardiovascular diseases 2007;50(3):209-17

PMID: 17976505

Full Text on Elsevier Science View on PubMed

Abstract

The patient with abdominal aortic aneurysm (AAA) commonly is a nondiabetic, white man with a history of smoking. Moreover, AAA represents a leading cause of death in elderly men in Western countries. The purpose of this manuscript is to review current evidence as to the pathobiology of AAA as well as potential future drug targets to prevent progression of AAA.

Address: Division of Clinical and Interventional Angiology, Swiss Cardiovascular Center, University Hospital and University of Bern, Bern, Switzerland.

DOI: 10.1016/j.pcad.2007.05.001

Link outs

Free resources

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

MeSH Terms: Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Aorta, Aortic Aneurysm, Abdominal, Atherosclerosis, Cardiovascular Agents, Extracellular Matrix Proteins, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Inflammation, MAP Kinase Kinase 4, Male, Oxidative Stress, Peptide Hydrolases, Protease Inhibitors, Risk Factors, Vitamins